Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (888)	12/18/1997 8:38:00 AM
From: EZLibra	Respond to of 3702

NO, not the buildings! They belong to us, the shareholders, and supposedly are worth more than was paid for them. Maybe a neutron bomb? On financing the company has indicated that funds to be raised would come from licensing. Lym-1 can definitely be labled a source of funds. Any equity involved would have to be part of a package and would come at a premium (if I recall correctly ACY paid twice market for their stake). What is a large amount to TCLN is a pittance to future licensees. As to the stock price I think it is more of a message from the market to current management to become past management than anything else. The CEO's resignation at CYTO yesterday added 50 million to their market cap, the same scene at TCLN could double the stock price, at least temporarily. I have not heard of any selling that would result from a CEO resignation, quite the opposite in fact. Since it's going to happen anyway the stock selloff is silly. The question is whether or not this is the best level to buy more. And that is the $64,000 question.

To: shero who wrote (888)	12/18/1997 8:50:00 AM
From: WWS	Respond to of 3702

Shero, I've been through "the blame game" before--with IDPH. In 1994 I bought at 5 and then watched my investment shrink to 2.5. What happened thereafter is the stuff of which legends are made: iqc.com The point is that, to my eye, TCLN resembles an early version of IDPH, considering that the bulk of IDPH's growth has been on the strength of a single product for the NHL market. So, am I really that upset by my inability to pick the "true" bottom of TCLN stock price; not really. I like the story I hear of new management coming in, of new partnering options being pursued and of the broad product pipeline. To me, worth the gamble. Best Regards, Bill.